STP 705

Drug Profile

STP 705

Alternative Names: Anti-fibrosis RNA interference therapeutic - Sirnaomic; Cotsiranib; STP 705; STP-705LU; STP-705LV

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator General Research Laboratory; Sirnaomics
  • Developer General Research Laboratory; Guangzhou Xiangxue Pharmaceuticals; Sirnaomics
  • Class Anti-inflammatories; Antifibrotics; Small interfering RNA; Stem cell therapies
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; RNA inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertrophic scars
  • Preclinical Hepatic fibrosis; Wounds

Most Recent Events

  • 01 Aug 2017 STP 705 receives Orphan Drug status for Primary sclerosing cholangitis in USA
  • 15 Jun 2017 Pharmacodynamics data from preclinical trials in Fibrosis released by Sirnaomics
  • 01 May 2017 Chinese FDA approves IND application for STP 705 in Hypertrophic scras (In volunteers)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top